Sun Pharma pulls out from the race to acquire Swedish firm Meda Pharma

04 Jul 2013 Evaluate

Sun Pharmaceutical Industries, which has cash balance of $1.3 billion as on March this year including its subsidiary Taro Pharmaceutical Industries, was in talks with banks to raise funds for the acquisition of Swedish firm Meda Pharmaceuticals for up to $6 billion in June. However, on account of sharp depreciation of rupee in June and patent settlement worth $550 million in the US, has opted out from the race.

Rupee’s sharp fall in June has postponed the overseas acquisition plans of many Indian companies, including Sun Pharma. The rupee leads the losers' chart among Asian currencies in the April-June quarter by plunging 8.6%, during the period due to massive capital outflows on worries of withdrawal of the US stimulus and reported cash crunch in China.

Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1797.25 2.95 (0.16%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×